How does PD-L1 impact treatment options for lung cancer?

Dr. Edward Garon explains the role of a patient’s PD-L1 levels in lung cancer treatment decision making. PD-L1 is an important biomarker that can help physicians decide whether or not a patient may be eligible for immunotherapy. Learn more at

Support for this educational program provided by Amgen, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Genentech, Lilly Oncology, Merck, Novartis and Pfizer.


Leave a Reply

Your email address will not be published.